Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing

H. Huskova, M. Ardin, A. Weninger, K. Vargova, S. Barrin, S. Villar, M. Olivier, T. Stopka, Z. Herceg, M. Hollstein, J. Zavadil, M. Korenjak,

. 2017 ; 36 (43) : 6041-6048. [pub] 20170710

Language English Country Great Britain

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18016495

Grant support
NV16-27790A MZ0 CEP Register

Digital library NLK
Full text - Article

E-resources Online Full text

NLK ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1997-01-01
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago
Public Health Database (ProQuest) from 2000-01-01 to 1 year ago

Links

PubMed 28692054
DOI 10.1038/onc.2017.215
Knihovny.cz E-resources

The information on candidate cancer driver alterations available from public databases is often descriptive and of limited mechanistic insight, which poses difficulties for reliable distinction between true driver and passenger events. To address this challenge, we performed in-depth analysis of whole-exome sequencing data from cell lines generated by a barrier bypass-clonal expansion (BBCE) protocol. The employed strategy is based on carcinogen-driven immortalization of primary mouse embryonic fibroblasts and recapitulates early steps of cell transformation. Among the mutated genes were almost 200 COSMIC Cancer Gene Census genes, many of which were recurrently affected in the set of 25 immortalized cell lines. The alterations affected pathways regulating DNA damage response and repair, transcription and chromatin structure, cell cycle and cell death, as well as developmental pathways. The functional impact of the mutations was strongly supported by the manifestation of several known cancer hotspot mutations among the identified alterations. We identified a new set of genes encoding subunits of the BAF chromatin remodeling complex that exhibited Ras-mediated dependence on PRC2 histone methyltransferase activity, a finding that is similar to what has been observed for other BAF subunits in cancer cells. Among the affected BAF complex subunits, we determined Smarcd2 and Smarcc1 as putative driver candidates not yet fully identified by large-scale cancer genome sequencing projects. In addition, Ep400 displayed characteristics of a driver gene in that it showed a mutually exclusive mutation pattern when compared with mutations in the Trrap subunit of the TIP60 complex, both in the cell line panel and in a human tumor data set. We propose that the information generated by deep sequencing of the BBCE cell lines coupled with phenotypic analysis of the mutant cells can yield mechanistic insights into driver events relevant to human cancer development.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016495
003      
CZ-PrNML
005      
20180517110943.0
007      
ta
008      
180515s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/onc.2017.215 $2 doi
035    __
$a (PubMed)28692054
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Huskova, H $u Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France. Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic.
245    10
$a Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing / $c H. Huskova, M. Ardin, A. Weninger, K. Vargova, S. Barrin, S. Villar, M. Olivier, T. Stopka, Z. Herceg, M. Hollstein, J. Zavadil, M. Korenjak,
520    9_
$a The information on candidate cancer driver alterations available from public databases is often descriptive and of limited mechanistic insight, which poses difficulties for reliable distinction between true driver and passenger events. To address this challenge, we performed in-depth analysis of whole-exome sequencing data from cell lines generated by a barrier bypass-clonal expansion (BBCE) protocol. The employed strategy is based on carcinogen-driven immortalization of primary mouse embryonic fibroblasts and recapitulates early steps of cell transformation. Among the mutated genes were almost 200 COSMIC Cancer Gene Census genes, many of which were recurrently affected in the set of 25 immortalized cell lines. The alterations affected pathways regulating DNA damage response and repair, transcription and chromatin structure, cell cycle and cell death, as well as developmental pathways. The functional impact of the mutations was strongly supported by the manifestation of several known cancer hotspot mutations among the identified alterations. We identified a new set of genes encoding subunits of the BAF chromatin remodeling complex that exhibited Ras-mediated dependence on PRC2 histone methyltransferase activity, a finding that is similar to what has been observed for other BAF subunits in cancer cells. Among the affected BAF complex subunits, we determined Smarcd2 and Smarcc1 as putative driver candidates not yet fully identified by large-scale cancer genome sequencing projects. In addition, Ep400 displayed characteristics of a driver gene in that it showed a mutually exclusive mutation pattern when compared with mutations in the Trrap subunit of the TIP60 complex, both in the cell line panel and in a human tumor data set. We propose that the information generated by deep sequencing of the BBCE cell lines coupled with phenotypic analysis of the mutant cells can yield mechanistic insights into driver events relevant to human cancer development.
650    _2
$a zvířata $7 D000818
650    _2
$a nádorová transformace buněk $x genetika $7 D002471
650    _2
$a exom $x genetika $7 D059472
650    _2
$a fibroblasty $7 D005347
650    12
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a mutace $7 D009154
650    _2
$a nádorové proteiny $x genetika $7 D009363
650    _2
$a nádory $x genetika $7 D009369
650    _2
$a primární buněčná kultura $7 D061251
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ardin, M $u Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France.
700    1_
$a Weninger, A $u Deutsches Krebsforschungszentrum, Heidelberg, Germany.
700    1_
$a Vargova, K $u Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Barrin, S $u Dynamics of T cell Interactions Team, Institut Cochin, Inserm U1016, Paris, France.
700    1_
$a Villar, S $u Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France.
700    1_
$a Olivier, M $u Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France.
700    1_
$a Stopka, T $u Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Herceg, Z $u Epigenetics Group, International Agency for Research on Cancer, Lyon, France.
700    1_
$a Hollstein, M $u Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France. Deutsches Krebsforschungszentrum, Heidelberg, Germany. Faculty of Medicine and Health, University of Leeds, LIGHT Laboratories, Leeds, UK.
700    1_
$a Zavadil, J $u Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France.
700    1_
$a Korenjak, M $u Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France.
773    0_
$w MED00003600 $t Oncogene $x 1476-5594 $g Roč. 36, č. 43 (2017), s. 6041-6048
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28692054 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180517111120 $b ABA008
999    __
$a ok $b bmc $g 1300119 $s 1013335
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 36 $c 43 $d 6041-6048 $e 20170710 $i 1476-5594 $m Oncogene $n Oncogene $x MED00003600
GRA    __
$a NV16-27790A $p MZ0
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options